Aeluma heads into the post-earnings session with a revenue miss and a guidance cut — the headline tension being that a stock up 152% in a month just delivered Q3 results that disappointed on both top line and forward outlook.
The company reported Q3 adjusted EPS of -$0.04, in line with estimates. But revenue came in at $1.22M, short of the $1.35M consensus, and management narrowed FY2026 sales guidance to $4.2M–$4.6M — a range whose midpoint sits well below the prior Street estimate of $5.37M. The earnings call transcript published the same evening, and the stock was already trading lower on the day at $27.11, down 3.8% on Tuesday. The stock had hit a new 52-week high earlier in the week before pulling back sharply.
Short positioning adds another layer of complexity. Short interest amounts to 18.6% of the free float — a genuinely elevated level for a company of this size — and has climbed roughly 21% over the past month as the stock surged. That said, shorts trimmed modestly this week, with SI falling 5.6% from last week's levels. The borrow market has loosened considerably: availability of shares-to-borrow relative to short interest has widened to 75%, and cost to borrow has dropped to 1.44% annually, down nearly 47% on the week — its lowest reading in the 30-day window. That combination of easing borrow costs and improving availability suggests the lending market is not being squeezed, even as short interest remains high. The ORTEX short score eased slightly to 69.2, down from a recent peak above 71, reflecting the modest de-risking by shorts.
Options traders are not adding directional pressure either. The put/call ratio of 0.33 is essentially in line with its 20-day average of 0.32, with a near-zero z-score. Call open interest continues to outweigh puts by a wide margin — the 52-week high on PCR was only 0.57, suggesting this name's options market has been consistently call-heavy all year. There is no sign of a defensive hedging spike into earnings.
The Street's bullish consensus runs thin in terms of coverage breadth. Only two analysts formally cover the stock, both carrying Buy ratings. Benchmark reiterated its Buy and $25 target as recently as March, while Freedom Broker initiated coverage at Buy with a $23 target in late March. The mean price target of $25.50 now sits below the current price of $27.11 — a gap that may become harder to justify given the guidance cut. Bulls point to Aeluma's optoelectronic technology platform and NVIDIA's strategic investment as differentiators in AI and defense applications; bears flag intense competition in mobile handset markets, thin revenues, and heavy dependence on a narrow customer base. The negative P/E and EV/EBITDA multiples reflect a company still burning cash at this stage.
Insider selling has been consistent and material. CEO Jonathan Klamkin sold approximately 20,000 shares in early April at around $13, then sold a further 20,000 shares in May at prices between $24 and $26 — collectively generating over $760,000. Net insider activity over 90 days shows a cumulative sale of around $3.2M worth of shares. Director Steven DenBaars also trimmed 25,000 shares in late February. The pattern of insider selling accelerating as the stock rallied is a relevant piece of context. After the last comparable earnings event in early May, the stock fell 14% the following day — the only prior print with reaction data — though the circumstances then differed.
The next scheduled earnings event is September 9. Between now and then, how the stock absorbs the guidance cut — and whether the revised $4.2M–$4.6M sales range proves achievable given Q3's miss — will determine whether the short interest at nearly 19% of float starts moving back toward levels seen before the stock's explosive April run.
See the live data behind this article on ORTEX.
Open ALMU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
